Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:0
|
作者
Georgios Kontorinis
Jaya Nichani
Simon R. Freeman
Scott A. Rutherford
Samantha Mills
Andrew T. King
Deborah Mawman
Sue Huson
Martin O’Driscoll
D. Gareth Evans
Simon K. W. Lloyd
机构
[1] Central Manchester University Hospitals NHS Foundation Trust,University Department of Otolaryngology
[2] Salford Royal NHS Foundation Trust,Department of Neurosurgery
[3] Salford Royal NHS Foundation Trust,Department of Neuroradiology
[4] Central Manchester University Hospitals NHS Foundation Trust,Department of Genetics Medicine
[5] University of Manchester,School of Cancer and Enabling Services
[6] Southern Teaching Hospital,Department of Otolaryngology, Institute of Neurosciences
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8–21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p =  0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7–19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients’ age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:7
相关论文
共 50 条
  • [31] Pediatric unilateral sensorineural hearing loss: implications and management
    Dornhoffer, James R.
    Dornhoffer, John L.
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2016, 24 (06): : 522 - 528
  • [32] Progress in the diagnosis and management of neurofibromatosis
    Korf, BR
    FAMILIAL CANCER AND PREVENTION: MOLECULAR EPIDEMIOLOGY - A NEW STRATEGY TOWARD CANCER CONTROL, 1999, : 455 - 459
  • [33] Options and strategies for hearing restoration in pediatric neurofibromatosis type 2
    Hossein Mahboubi
    William H. Slattery
    Gautam U. Mehta
    Gregory P. Lekovic
    Child's Nervous System, 2020, 36 : 2481 - 2487
  • [34] Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
    Plotkin, Scott R.
    Stemmer-Rachamimov, Anat O.
    Barker, Fred G., II
    Halpin, Chris
    Padera, Timothy P.
    Tyrrell, Alex
    Sorensen, A. Gregory
    Jain, Rakesh K.
    di Tomaso, Emmanuelle
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (04): : 358 - 367
  • [35] Options and strategies for hearing restoration in pediatric neurofibromatosis type 2
    Mahboubi, Hossein
    Slattery, William H., III
    Mehta, Gautam U.
    Lekovic, Gregory P.
    CHILDS NERVOUS SYSTEM, 2020, 36 (10) : 2481 - 2487
  • [36] Type 2 diabetes and hearing loss
    Hong, OiSaeng
    Buss, Julia
    Thomas, Elizabeth
    DM DISEASE-A-MONTH, 2013, 59 (04): : 139 - 146
  • [37] Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions
    Yuan, Ruofei
    Wang, Bo
    Wang, Ying
    Liu, Pinan
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 257 - 276
  • [38] Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results
    Peyre, Matthieu
    Goutagny, Stephane
    Bah, Alpha
    Bernardeschi, Daniele
    Larroque, Beatrice
    Sterkers, Olivier
    Kalamarides, Michel
    NEUROSURGERY, 2013, 72 (06) : 907 - 913
  • [39] Incidence of Hearing Loss in Patients With Neurofibromatosis Type 1 at a Tertiary Care Pediatric Hospital
    Yun, Alice
    Grif, Amanda M.
    Kim, Hae-Young
    Ullrich, Nicole J.
    Licameli, Greg R.
    PEDIATRIC NEUROLOGY, 2024, 159 : 35 - 40
  • [40] NEUROFIBROMATOSIS TYPE-1 - A RARE CASE RESULTING IN CONDUCTIVE HEARING-LOSS
    MCKENNAN, KX
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1991, 104 (06) : 868 - 872